Exhibit 99.1

U.S. EpiPen Profitability Analysis

Following Mylan’s recent testimony before the United States House of Representatives regarding EpiPen, Mylan is providing this analysis of the profitability in the United States of EpiPen as a supplement to its testimony. Mylan does not regularly provide profitability analyses for individual products and does not intend in the future to provide product level profitabilty analysis for EpiPen or to update this analysis.

(In USD millions)	2008		2009		2010		2011		2012		2013		2014		2015		2016E [3]
Sales		184		200		281		371		622		742		933		912		1,100
Cost of Goods Sold		79		86		123		139		195		202		224		255		275
Gross Profit		105		114		158		232		427		540		709		657		825
Gross Margin		57.1%		57.0%		56.2%		62.5%		68.6%		72.8%		76.0%		72.0%		75.0%
Operating Costs [1]		34		32		43		58		121		147		184		159		154
Operating Profit		71		82		115		174		306		393		525		498		671
Estimated Implied Interest [2]		67		66		65		62		56		42		24		-		-
Estimated Tax Impact		2		6		19		42		94		132		188		187		252
Tax Rate [4]		37.5%		37.5%		37.5%		37.5%		37.5%		37.5%		37.5%		37.5%		37.5%
Net Product Profitability		3		10		31		70		156		219		313		312		419
US Pens Sold (millions)		4.3		4.5		5.2		5.5		7.3		7.4		7.9		8.3		8.0
Approximate US Metrics per Pen (in dollars):
Sales		43		44		54		67		85		100		118		110		137
Cost of Goods Sold		18		19		24		25		27		27		28		31		34
Gross Profit		24		25		30		42		58		73		90		79		103
Operating Cost		8		7		8		11		17		20		23		19		19
Operating Profit		17		18		22		32		42		53		66		60		83
Net Product Profitability		1		2		6		13		21		30		40		38		52

[1] Includes direct selling, marketing, medical affairs and R&D expenses. Does not include corporate allocations or the cost of the EpiPen4Schools program.

[2] Assumes interest on the unrecovered original investment at the actual weighted average borrowing rate of 7.9% for the debt incurred with the acquisition. Approximately $850M of the acquisition price attributed to EpiPen.

[3] Before changes to patient access programs and the launch of the authorized generic.

[4] The statutory tax rate for the U.S. has been used in this product line profitability analysis.

This analysis is derived in part from data prepared in accordance with generally accepted accounting principles (“GAAP”), and a reconciliation of the EpiPen operating profit to the segment profitability of Mylan’s Specialty Segment is included below. As used in this analysis, however, net product profitability for the EpiPen product and net product profitability per EpiPen unit sold are not GAAP measures and also reflect adjustments for estimated implied interest expense and for the impact of estimated taxes that have not been determined in accordance with GAAP and are not directly derived from Mylan’s reported results. Mylan does not have 2016 GAAP guidance, and consequently cannot provide a reconciliation for 2016E to Specialty Segment profitability or Consolidated results without unreasonable effort, because it is unable to predict with reasonable certainty the ultimate outcome of certain significant items required for the reconciliation. These items include, but are not limited to, acquisition-related expenses including those related to the recently closed Meda transaction, restructuring expenses, asset impairments, litigation settlements, changes to contingent consideration and certain other gains or losses. These items are uncertain, depend on various factors, and could have a material impact on U.S. GAAP reported results for the guidance period.

	2008			2009			2010		2011		2012		2013		2014		2015
EpiPen operating profit		71			82			115		174		306		393		525		498
Other Specialty Segment profitability		(34	)		(12	)		8		66		13		69		140		173
Specialty Segment profitability		37			70			123		240		319		462		665		671